Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Razelle Kurzrock(Medical College of Wisconsin), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Abedul Haque(The University of Texas MD Anderson Cancer Center), Sadakatsu Ikeda(Center for Personalized Cancer Treatment), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Roberto Carmagnani Pestana(The University of Texas MD Anderson Cancer Center), Bhawana George(The University of Texas MD Anderson Cancer Center), Andrea Grace Bocobo(University of California, San Francisco), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Marc Uemura(The University of Texas MD Anderson Cancer Center), James C. Yao(The University of Texas MD Anderson Cancer Center), Kimberly C. Banks(Guardant (United States)), AmirAli Talasaz(Guardant (United States)), Nora Sánchez(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Kenna R. Mills-Shaw(The University of Texas MD Anderson Cancer Center), Kian‐Huat Lim(Washington University in St. Louis), Wei Qiao(The University of Texas MD Anderson Cancer Center), Reham Abdel‐Wahab(Assiut University), Shiraj Sen(The University of Texas MD Anderson Cancer Center), Asif Rashid(American International University-Bangladesh), Benjamin Tan(Washington University in St. Louis), Jeffrey S. Morris(The University of Texas MD Anderson Cancer Center), Manal M. Hassan(The University of Texas MD Anderson Cancer Center), Hesham M. Amin(The University of Texas MD Anderson Cancer Center)
Cited by 76
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k